Viking Therapeutics, Inc. (VKTX)

Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

3 Absurdly Cheap Stocks to Buy Before the End of 2026

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

VKTX Advances Obesity Program With New Oral Maintenance Study

VKTX Down 16% in a Month: Time to Invest or Exit the Stock?

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

Here Are My Top 4 Stocks to Buy in October

LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies

Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?

Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors

Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy

Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

3 Non-AI Growth Stocks That Have Massive Upside